Mass Cytometry to Decipher the Mechanism of Nongenetic Drug Resistance in Cancer

作者: Harris G. Fienberg , Garry P. Nolan

DOI: 10.1007/82_2014_365

关键词:

摘要: Nongenetic resistance has recently been described as a major impediment to effective cancer therapy. is challenging study since it occurs nonuniformly, even in cell lines, and can involve the interplay of multiple survival pathways. Until recently, no technology allowed measurement large-scale alterations pathways with single-cell resolution. Mass cytometry, flow-based technique which activation up 50 proteins be measured simultaneously single-cell, now provides ability examine nongenetic on functional level cell-by-cell basis. The application mass combination new bioinformatic techniques, will allow fundamental questions addressed: Is caused by selection cells pre-existing phenotype or induction program? Which are necessary for how do they interact? Currently, cytometry being used investigate mechanism TRAIL-induced apoptosis. approaches developed understand TRAIL likely applied elucidate mechanisms broadly clinic.

参考文章(38)
Tyler J. Curiel, Matthew E. Burow, Christine M. Dugan, Jawed Alam, Barbara S. Beckman, Christopher B. Weldon, John L. Clayton, Daniel E. Frigo, Amanda P. Parker, Nancy N. Butler, Bernard M. Jaffe, Daniel Patten, Erin L. Coakley, Yan Tang, Steven Elliott, Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. International Journal of Oncology. ,vol. 24, pp. 1473- 1480 ,(2004) , 10.3892/IJO.24.6.1473
Vanessa S. Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C. Pagano, Poulikos I. Poulikakos, Maurizio Scaltriti, Elizabeth Moskatel, José Baselga, Sylvie Guichard, Neal Rosen, mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling Cancer Discovery. ,vol. 1, pp. 248- 259 ,(2011) , 10.1158/2159-8290.CD-11-0085
El-ad David Amir, Kara L Davis, Michelle D Tadmor, Erin F Simonds, Jacob H Levine, Sean C Bendall, Daniel K Shenfeld, Smita Krishnaswamy, Garry P Nolan, Dana Pe'er, viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia Nature Biotechnology. ,vol. 31, pp. 545- 552 ,(2013) , 10.1038/NBT.2594
Andriy Marusyk, Vanessa Almendro, Kornelia Polyak, Intra-tumour heterogeneity: a looking glass for cancer? Nature Reviews Cancer. ,vol. 12, pp. 323- 334 ,(2012) , 10.1038/NRC3261
Ricky W. Johnstone, Ailsa J. Frew, Mark J. Smyth, The TRAIL apoptotic pathway in cancer onset, progression and therapy Nature Reviews Cancer. ,vol. 8, pp. 782- 798 ,(2008) , 10.1038/NRC2465
Sabrina L. Spencer, Peter K. Sorger, Measuring and Modeling Apoptosis in Single Cells Cell. ,vol. 144, pp. 926- 939 ,(2011) , 10.1016/J.CELL.2011.03.002
Nand K. Sah, Anupama Munshi, John F. Kurland, Timothy J. McDonnell, Bing Su, Raymond E. Meyn, Translation Inhibitors Sensitize Prostate Cancer Cells to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) by Activating c-Jun N-terminal Kinase Journal of Biological Chemistry. ,vol. 278, pp. 20593- 20602 ,(2003) , 10.1074/JBC.M211010200
Thomas Newsom-Davis, Silvia Prieske, Henning Walczak, None, Is TRAIL the holy grail of cancer therapy? Apoptosis. ,vol. 14, pp. 607- 623 ,(2009) , 10.1007/S10495-009-0321-2
Deborah A Flusberg, Peter K Sorger, None, Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging. Physical Biology. ,vol. 10, pp. 035002- 035002 ,(2013) , 10.1088/1478-3975/10/3/035002
L Y Dimberg, C K Anderson, R Camidge, K Behbakht, A Thorburn, H L Ford, On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. ,vol. 32, pp. 1341- 1350 ,(2013) , 10.1038/ONC.2012.164